August 5, 2026
9:44 pm

Congestive Heart Failure and Life Settlement Eligibility

Congestive heart failure is one of the most commonly accepted conditions in the life settlement market, and a documented CHF diagnosis generally improves rather than harms the market value of a policy — provided the policy itself qualifies on size, type, and premium cost. That is the direct answer. CHF is chronic, progressive, well documented in medical records, and supported by objective measurements underwriters trust. Those four traits are exactly what a life expectancy underwriter needs.

What surprises most families is the direction of the relationship. In the primary insurance market, health problems make coverage expensive or unavailable. In the secondary market, the calculation inverts: a buyer is estimating how long premiums must be paid before the death benefit is collected, so a shorter documented life expectancy raises what a policy is worth.

This page covers which clinical details matter, how CHF pricing actually works, how every alternative compares, and the circumstances in which keeping or surrendering the policy is genuinely the better decision. Pine Lake Life Solutions offers education and a free policy review, not medical, legal, or tax advice.

In This Article

The Clinical Details Underwriters Actually Read
Why a Serious Diagnosis Raises Market Value
The Policy Still Has to Qualify Independently
Every Alternative, Compared Fairly
When a Settlement Is the Wrong Call With CHF
Numbers, Timing, and the Documentation Trail
How to Get a Real Answer
Frequently Asked Questions

Congestive Heart Failure and Life Settlement Eligibility

The Clinical Details Underwriters Actually Read

An underwriter reviewing a CHF file is not reading the word failure; they are reading numbers. The New York Heart Association functional classification, running from Class I with no limitation of activity to Class IV with symptoms at rest, is the standard framework and appears in most cardiology notes. Left ventricular ejection fraction from an echocardiogram is the second anchor, along with whether the failure is classified as reduced ejection fraction or preserved ejection fraction.

Beyond that: hospitalization history, because repeat admissions for decompensation are a strong signal; implanted devices such as an ICD or a cardiac resynchronization device; medication regimen and whether the patient is tolerating guideline-directed therapy; renal function, since cardiorenal interaction meaningfully shortens estimates; and comorbidities like diabetes, atrial fibrillation, prior myocardial infarction, or COPD. A complete cardiology record produces a defensible estimate. A thin record produces a conservative one, which usually means a lower offer.

Why a Serious Diagnosis Raises Market Value

A buyer’s economics are simple: purchase price, plus every premium paid until the insured’s death, must be less than the death benefit by enough to justify the capital and the risk. Shorten the projected holding period and the acceptable purchase price rises. That is the entire mechanism.

It is also why two people with identical $500,000 policies can get very different offers. The healthier insured, with a projected life expectancy of eighteen years, represents eighteen years of premium outlay before any return. The insured with NYHA Class III heart failure and a documented hospitalization history represents a much shorter horizon. Neither person is being judged; the market is pricing a cash-flow problem. Our page on what affects a life settlement offer breaks the variables down.

The Policy Still Has to Qualify Independently

Health is only one of two gates. The policy has to clear its own screen. Death benefit of roughly $100,000 or more is the practical floor, because underwriting, escrow, legal, and servicing costs are largely fixed. Universal life, guaranteed universal life, whole life, and convertible term are all commonly transacted; non-convertible term generally is not, because it will expire before it pays.

Cost of insurance matters as much as face amount. A guaranteed universal life policy with a low, level premium and a $500,000 death benefit is far more attractive than a policy of the same size whose internal charges are escalating steeply with age. Outstanding policy loans reduce any offer dollar for dollar. And policies still inside the two-year contestability period are generally avoided. See the minimum policy size for the full screen.

Clinical Factor	What Underwriters Look At	Typical Effect on Value
NYHA class	Class I-IV functional limitation	Higher class, higher value
Ejection fraction	Echocardiogram, reduced vs. preserved	Lower EF generally raises value
Hospitalizations	Frequency of decompensation admissions	Repeat admissions raise value
Renal function	Cardiorenal involvement	Impairment raises value
Device therapy	ICD, CRT, LVAD	Case-specific; can cut either way
Record completeness	Cardiology notes, imaging, med list	Thin records lower offers

The Policy Still Has to Qualify Independently

Every Alternative, Compared Fairly

Keep the policy. If a spouse or dependent will need the death benefit and premiums are affordable, keeping is correct. Beneficiaries generally receive death proceeds income-tax-free under Internal Revenue Code section 101(a)(1) — a durable advantage no lump sum replicates.

Chronic illness or accelerated death benefit rider. Check the rider schedule first. Chronic illness riders typically trigger on the inability to perform two of six activities of daily living or on severe cognitive impairment, certified by a licensed health practitioner within the last 12 months. Advanced heart failure often meets that standard. Payments under a qualifying rider are generally excluded from income under Internal Revenue Code section 101(g), subject to statutory conditions and, for chronically ill insureds, annual per-diem limits — confirm the 2026 limit with your tax advisor.

Policy loan. Keeps the contract alive and provides cash, but interest accrues and an unpaid loan reduces the benefit. Watch for a policy where loan interest is eroding cash value faster than credits are added.

Reduced paid-up insurance. A nonforfeiture option on permanent policies: stop premiums, keep a smaller fully paid death benefit. Ideal when the problem is premium strain rather than a need for cash. Compare with reduced paid-up vs. a settlement.

1035 exchange. Internal Revenue Code section 1035 allows a tax-free exchange into another life policy, an annuity, or a qualified long-term care contract. Rarely the best move for an insured with advanced CHF, because the exchange trades a death benefit already underwritten at a healthier age for a new product.

Surrender. Pays only cash surrender value and is usually the lowest-value exit for a policy that the secondary market would value more highly.

Life or viatical settlement. A lump sum today, appropriate when the coverage is no longer needed, premiums are a strain, or care costs are immediate.

When a Settlement Is the Wrong Call With CHF

Three situations argue clearly against selling. First, a surviving spouse who will depend on the death benefit for income — cash equal to 10% to 35% of face value is a poor substitute for the full benefit, and heart failure prognoses vary widely. Second, an affordable premium with no cash need; there is simply no forcing event. Third, a policy with a rich chronic illness rider that would pay a substantial portion of the death benefit with no commission, no broker, and favorable tax treatment.

Surrendering can also beat selling in one narrow case: a small policy, well under $100,000, with substantial cash value relative to face amount. There the secondary market will not be interested and the carrier’s check is the best available exit.

Numbers, Timing, and the Documentation Trail

The federal reference point remains the U.S. Government Accountability Office’s market study (GAO-10-775), which found sellers typically received roughly 10% to 35% of face value and, on average, several times what surrender would have paid — commonly summarized as 4 to 8 times cash surrender value. CHF cases with well-documented advanced disease tend to fall toward the upper part of that band; early, well-controlled Class I or II disease tends toward the lower part or draws no offer at all.

The process runs roughly 60 to 120 days. Expect to sign a HIPAA authorization complying with 45 CFR 164.508, which must state an expiration date and your right to revoke. Expect one or two independent life expectancy reports. Expect funds to sit in independent escrow until the carrier records the change of ownership, and expect a state-law rescission window after funding — commonly 15 to 30 days, though the length varies by state, so confirm yours.

How to Get a Real Answer

Start with three documents: the policy cover page showing insurer, policy number, face amount, and issue date; the most recent annual statement showing cash value and any loan; and the rider schedule. If you can also identify the treating cardiologist and the approximate date of the most recent echocardiogram, the preliminary read gets sharper.

Send the cover page for a free, no-obligation policy review, or call (305) 209-7183. If the honest answer is that the policy is too small, the disease too early, or the family’s need too great, you will be told that. This page is educational information only and is not medical, legal, or tax advice; discuss your situation with your own physician, attorney, and CPA.

Frequently Asked Questions

Does congestive heart failure disqualify me from selling a policy?

No. CHF is among the most commonly accepted conditions in the secondary market because it is chronic, progressive, and objectively documented. A documented diagnosis generally raises what a qualifying policy is worth rather than lowering it.

What clinical information will the underwriter want?

Typically NYHA functional class, ejection fraction from a recent echocardiogram, hospitalization history, current medications, renal function, and any implanted cardiac devices. Comorbidities such as diabetes, atrial fibrillation, or COPD are also factored in. Complete records produce better and faster assessments.

Is my policy too small to sell?

The practical floor is a death benefit of roughly $100,000, because underwriting, escrow, and legal costs are largely fixed regardless of policy size. Below that, the market rarely engages. Small policies with meaningful cash value are usually better handled through the carrier.

Should I claim a chronic illness rider instead?

If your policy has one and you meet its trigger, it is often the better first move. Riders typically require inability to perform two of six activities of daily living or severe cognitive impairment, certified by a licensed health practitioner. Qualifying payments generally receive favorable treatment under IRC section 101(g).

How much might a CHF case be worth?

The GAO market study (GAO-10-775) found sellers typically received roughly 10% to 35% of face value. Advanced, well-documented heart failure tends toward the upper part of that band, while early and well-controlled disease tends toward the lower part or draws no offer. Only a review of your actual file produces a number.

How long does the process take?

Roughly 60 to 120 days from initial review to funded payment. The medical record retrieval and life expectancy underwriting are usually the longest steps. Most states then provide a rescission window after funding, commonly 15 to 30 days, so confirm your state’s rule.

Will selling affect my Medicare or Social Security?

Medicare and Social Security retirement benefits are not means-tested, so proceeds generally do not affect them. Needs-based programs such as Medicaid and SSI are a different matter, because a lump sum becomes a countable resource. Coordinate timing with an elder law attorney before closing.

Find out what your policy is worth — free, confidential, no obligation.

A 15-minute educational review covers your eligibility, every alternative, and a realistic view of what each path would net you.

Call (305) 209-7183 · Request a review online →

Table of Contents